| Therapeutics – Adressing high unmet medical needs |
Many diseases are still incurable today. The successful treatment of one disease often is followed by subsequent medical needs arising from treatment-related side effect, reoccurrence or chronicity.
Wellington is especially interested in financing the development of innovative therapeutic approaches addressing high unmet medical needs. These innovative therapeutics may be based on novel pathways and targets, proteins and peptides, nucleic acid-based drugs, cell-based therapies and drug delivery technologies. By applying the highest industry standards to product development processes and defining the appropriate target indications and life cycle management strategies early on, young biotech companies and start-ups can generate enormous growth and value. Once a strong preclinical and clinical proof of concept has been demonstrated, companies can benefit from exceptional market opportunities provided by the steadily rising need of big pharma players to add new drug candidates to their pipelines.
